Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1963 2
1965 2
1966 2
1967 1
1968 3
1969 1
1970 3
1971 6
1972 6
1973 4
1974 9
1975 6
1976 5
1977 10
1978 11
1979 6
1980 11
1981 18
1982 10
1983 25
1984 21
1985 16
1986 19
1987 23
1988 16
1989 22
1990 20
1991 24
1992 26
1993 19
1994 20
1995 21
1996 21
1997 19
1998 29
1999 30
2000 35
2001 49
2002 34
2003 45
2004 58
2005 69
2006 36
2007 53
2008 69
2009 71
2010 87
2011 93
2012 95
2013 93
2014 96
2015 121
2016 126
2017 145
2018 93
2019 137
2020 144
2021 158
2022 151
2023 145
2024 137
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,559 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. Among authors: kudo m. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Cheng AL, et al. Among authors: kudo m. J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11. J Hepatol. 2022. PMID: 34902530 Free article. Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Among authors: kudo m. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Among authors: kudo m. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Therapeutic Potential of Centella asiatica and Its Triterpenes: A Review.
Sun B, Wu L, Wu Y, Zhang C, Qin L, Hayashi M, Kudo M, Gao M, Liu T. Sun B, et al. Among authors: kudo m. Front Pharmacol. 2020 Sep 4;11:568032. doi: 10.3389/fphar.2020.568032. eCollection 2020. Front Pharmacol. 2020. PMID: 33013406 Free PMC article. Review.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Yau T, et al. Among authors: kudo m. Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13. Lancet Oncol. 2022. PMID: 34914889 Clinical Trial.
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Omata M, et al. Among authors: kudo m. Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15. Hepatol Int. 2017. PMID: 28620797 Free PMC article. Review.
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Yau T, et al. Among authors: kudo m. JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12. JAMA Oncol. 2020. PMID: 33001135 Free PMC article. Clinical Trial.
Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.
Sekiguchi Y, Tsutsumi H, Gomyo A, Kudo M, Iizaki Y, Maseki N, Kawamura M, Kobayashi K, Nishimura Y, Kanda H, Nitta H, Noguchi M, Kobayashi H. Sekiguchi Y, et al. Among authors: kudo m. J Clin Exp Hematop. 2023;63(4):262-265. doi: 10.3960/jslrt.23043. J Clin Exp Hematop. 2023. PMID: 38148017 Free PMC article. No abstract available.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Among authors: kudo m. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
2,559 results